Antengene and UCB Enter Global License Agreement for ATG-201, a CD19/CD3 Bispecific T-Cell Engager for Autoimmune Diseases
PR Newswire —
Antengene grants UCB worldwide exclusive rights to develop, manufacture and commercialize ATG-201, a CD19/CD3 bispecific T-cell engager (TCE) antibody, targeting B cell-related autoimmune diseases. Antengene will receive USD 80 million of upfront and near-term milestone payments, and is...